Literature DB >> 26454391

Retinal Screening Acceptance, Laser Treatment Uptake and Follow-up Response in Diabetics Requiring Laser Therapy in an Urban Diabetes Care Centre.

Salah Memon1, Shahid Ahsan2, Rashid Alvi3, Asher Fawwad4, Abdul Basit5, Samad Shera3, Sikander Ali Sheikh6, Muhammad Faisal Fahim7.   

Abstract

OBJECTIVE: To determine the acceptance of retinal screening, Laser uptake and subsequent follow-up in diabetic patients attending the Diabetes Centre of Diabetic Association of Pakistan (DAP), Karachi. STUDY
DESIGN: Observational case series. PLACE AND DURATION OF STUDY: Diabetic Centre of Diabetic Association of Pakistan (DAP), Karachi, from January 2011 to December 2012.
METHODOLOGY: All the diabetic patients were screened for Diabetic Retinopathy (DR) with non-Mydriatic Fundus Camera (NMFC). Patients with DR were examined by the ophthalmologist using fundus lens and slit lamp. DR was graded for severity on the basis of modified Airlie House Classification. Patients with Sight Threatening Diabetic Retinopathy (STDR) were advised Laser treatment. Each patient was followed-up for at least 6 months. The records of patients recommended Laser were retrieved, and called for re-examination.
RESULTS: Retinal screening was accepted by all of the 8368 registered diabetics attending DAP Centre. On fundus photography, 21.2% (1777) individuals were found to have DR. Seven hundred and five (39.5%) patients were found to have STDR. Laser was advised to 96.4% (680) of STDR patients; amongst whom 70.5% (480) accepted Laser treatment. Out of 480 patients who had Laser treatment, 21.2% (107) turned out for follow-up after 6 months.
CONCLUSION: Acceptance of retinal screening and Laser application was good; but follow-up was suboptional.

Entities:  

Mesh:

Year:  2015        PMID: 26454391     DOI: 10.2015/JCPSP.743746

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN: 1022-386X            Impact factor:   0.711


  6 in total

1.  Visual outcome of laser treatment in diabetic macular edema: Study from an Urban Diabetes Care Center.

Authors:  Rashid Alvi; Muhammad Saleh Memon; Samad Shera; Seema N Mumtaz; Sikander Ali Shaikh; Muhammad Faisal Fahim
Journal:  Pak J Med Sci       Date:  2016 Sep-Oct       Impact factor: 1.088

2.  Outcomes of intravitreal bevacizumab and macular photocoagulation for treatment of diabetic macular edema in a tertiary care eye hospital, Karachi.

Authors:  Adil Salim Jafri; Abdul Haleem Mirani; Saleh Memon
Journal:  Pak J Med Sci       Date:  2017 Sep-Oct       Impact factor: 1.088

3.  Effectiveness of interventions to increase uptake and completion of treatment for diabetic retinopathy in low- and middle-income countries: a rapid review protocol.

Authors:  Covadonga Bascaran; Nyawira Mwangi; Fabrizio D'Esposito; Charles Cleland; Iris Gordon; Juan Alberto Lopez Ulloa; Ranad Maswadi; Shaffi Mdala; Jacqueline Ramke; Jennifer R Evans; Matthew Burton
Journal:  Syst Rev       Date:  2021-01-14

4.  Strengthening the referral Chain and providing one window diabetes eye care facility to people with Type-2 Diabetes: A six-year follow-up study from Pakistan.

Authors:  Shahid Ahsan; Muhammad Saleh Memon; Muhammad Faisal Fahim; Tauseef Mahmood; Sikander Ali Sheikh
Journal:  Pak J Med Sci       Date:  2021 Nov-Dec       Impact factor: 1.088

5.  Implementation research on noncommunicable disease prevention and control interventions in low- and middle-income countries: A systematic review.

Authors:  Celestin Hategeka; Prince Adu; Allissa Desloge; Robert Marten; Ruitai Shao; Maoyi Tian; Ting Wei; Margaret E Kruk
Journal:  PLoS Med       Date:  2022-07-25       Impact factor: 11.613

6.  Transition from Laser to Intravitreal Injections for Diabetic Retinopathy: Hospital Utilization and Costs from an Extended Healthcare Perspective.

Authors:  Silvia Nanjala Walekhwa Hertzberg; Øystein K Jørstad; Beáta Éva Petrovski; Ragnheidur Bragadottir; Leif Arthur Steffensen; Morten Carstens Moe; Emily A Burger; Goran Petrovski
Journal:  Int J Environ Res Public Health       Date:  2022-10-02       Impact factor: 4.614

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.